Literature DB >> 15541380

Inactivation of the hMSH3 mismatch repair gene in bladder cancer.

Toshifumi Kawakami1, Hiroaki Shiina, Mikio Igawa, Masao Deguchi, Koichi Nakajima, Tatsuya Ogishima, Takashi Tokizane, Shinji Urakami, Hideki Enokida, Kazukiyo Miura, Nobuhisa Ishii, Christopher J Kane, Peter R Carroll, Rajvir Dahiya.   

Abstract

Deficiency in the DNA mismatch repair (MMR) is frequently involved in various cancers. The hMSH3 gene is one of the human MMR genes whose role in bladder cancer is not known. We hypothesized that down-regulation of the hMSH3 gene might be involved in bladder cancer. In this study we analyzed this gene with regard to frame-shift mutation, single nucleotide polymorphism (SNP), a 9bp repeat in exon 1, loss of heterozygosity (LOH), immunohistochemistry, and methylation status in 102 bladder cancer samples. Immunohistochemistry revealed that hMSH3 expression in bladder cancer was significant decreased compared to normal epithelium (p<0.0001). An inverse correlation with pathological grade was found. The frame-shift mutation in the (A) 8 tract was lacking in bladder cancer. There was no significantly difference between bladder cancer samples and healthy controls' with regard to SNP and the 9bp repeat. In bladder cancer, presence of the codon 222 polymorphism, LOH, and the 9bp repeats in exon 1 had a correlation with either pathological stage or pathological grade. Presence of the codon 1036 polymorphism had significant correlation with pathological stage and a trend to correlation with pathological grade. After 5-aza-dC treatment, MSH3 expression was significantly enhanced in TCC and UMUC bladder cancer cells when compared to untreated cells. This is the first report suggesting that genetic and epigenetic alterations in the human MSH3 gene might play a significant role in the progression of bladder tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15541380     DOI: 10.1016/j.bbrc.2004.10.114

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  The MutSβ complex is a modulator of p53-driven tumorigenesis through its functions in both DNA double-strand break repair and mismatch repair.

Authors:  J M M van Oers; Y Edwards; R Chahwan; W Zhang; C Smith; X Pechuan; S Schaetzlein; B Jin; Y Wang; A Bergman; M D Scharff; W Edelmann
Journal:  Oncogene       Date:  2013-09-09       Impact factor: 9.867

2.  Aberrant protein expression and frequent allelic loss of MSH3 in colorectal cancer with low-level microsatellite instability.

Authors:  Jens Plaschke; Mark Preußler; Andreas Ziegler; Hans K Schackert
Journal:  Int J Colorectal Dis       Date:  2012-01-10       Impact factor: 2.571

3.  Heterogeneity Analysis of Bladder Cancer Based on DNA Methylation Molecular Profiling.

Authors:  Shuyu Wang; Dali Xu; Bo Gao; Shuhan Yan; Yiwei Sun; Xinxing Tang; Yanjia Jiao; Shan Huang; Shumei Zhang
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

4.  MSH3 rs26279 polymorphism increases cancer risk: a meta-analysis.

Authors:  Hui-Kai Miao; Li-Ping Chen; Dong-Ping Cai; Wei-Ju Kong; Li Xiao; Jie Lin
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis.

Authors:  Rebecca A Mason; Elaine V Morlock; Margaret R Karagas; Karl T Kelsey; Carmen J Marsit; Alan R Schned; Angeline S Andrew
Journal:  Carcinogenesis       Date:  2009-04-16       Impact factor: 4.944

6.  Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer.

Authors:  Astrid C Haugen; Ajay Goel; Kanae Yamada; Giancarlo Marra; Thuy-Phuong Nguyen; Takeshi Nagasaka; Shinsaku Kanazawa; Junichi Koike; Yoshinori Kikuchi; Xiaoling Zhong; Michitsune Arita; Kazutoshi Shibuya; Mitsuo Oshimura; Hiromichi Hemmi; C Richard Boland; Minoru Koi
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

Review 7.  Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer.

Authors:  Philip H Abbosh; Elizabeth R Plimack
Journal:  Bladder Cancer       Date:  2018-01-20

8.  Inactivation of MSH3 by promoter methylation correlates with primary tumor stage in nasopharyngeal carcinoma.

Authors:  Haifeng Ni; Bo Jiang; Zhen Zhou; Xiaoyang Yuan; Xiaolin Cao; Guangwu Huang; Yong Li
Journal:  Int J Mol Med       Date:  2017-06-27       Impact factor: 4.101

9.  Haplotype of gene Nedd4 binding protein 2 associated with sporadic nasopharyngeal carcinoma in the Southern Chinese population.

Authors:  Mei-Zhen Zheng; Hai-De Qin; Xing-Juan Yu; Ru-Hua Zhang; Li-Zhen Chen; Qi-Sheng Feng; Yi-Xin Zeng
Journal:  J Transl Med       Date:  2007-07-13       Impact factor: 5.531

Review 10.  DNA Methylation as a Therapeutic Target for Bladder Cancer.

Authors:  Sandra P Nunes; Rui Henrique; Carmen Jerónimo; Jesús M Paramio
Journal:  Cells       Date:  2020-08-07       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.